Abstract Categories

36th Annual Meeting Abstract Categories

Primary Category and Subcategory

All abstract submitters will be asked to indicate the primary category and subcategory with which the abstract most closely aligns. This primary selection will aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. Accepted abstracts are also listed according to the primary category and subcategory selected within the JITC supplement and the Poster Hall.

Secondary Category and Subcategory

Should the submitter believe more than one category is applicable, they can select a secondary category and subcategory. The secondary category and subcategory will only be used aid the abstract reviewers in placing the abstract into the most appropriate session, if accepted for oral presentation. The secondary category and subcategory WILL NOT be used for the abstract listing in publications or placement in the Poster Hall.

*The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Abstracts will not be published in the Journal for ImmunoTherapy of Cancer (JITC) and are subject to a different timeline and review process than the 36th Annual Meeting Abstracts.

Clinical Trial Question

Abstract submitters must answer whether the abstract being submitted is based on a clinical trial and will be presenting clinical data. If the abstract being submit is a clinical trial abstract, please mark whether it is an in progress or completed clinical trial. For more information about what is considered a clinical trial in progress, please click here. If the abstract will incorporate basic or pre-clinical research, please mark that it is not a clinical trial abstract. Please note, the response to this question will determine which abstract categories you see as noted below.

Abstract Categories and Subcategory

Clinical Trial Abstract

If you respond “Yes” that the abstract is a clinical trial abstract, you will see the respective categories below:

1) Clinical Trial In Progress

  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancers
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. COVID and Immunotherapy
  14. Other

 

2) Clinical Trial Completed 

  1. Skin Cancers
  2. Lung Cancers
  3. Genitourinary Cancers
  4. Breast Cancers
  5. Gynecologic Cancers
  6. Hematologic Malignancies
  7. Brain and CNS Cancers
  8. Head and Neck Cancers
  9. Gastrointestinal/GEJ/Colorectal Cancers
  10. Hepatocellular Cancers
  11. Multi-Cancer
  12. Biomarker-Defined Cancers
  13. COVID and Immunotherapy
  14. Other

 


Non-Clinical Trial Abstract

If you respond “No” that the abstract is not a clinical trial abstract, you will see the categories below:

1) Checkpoint Blockade Therapy

  1. Response/Resistance Mechanisms
  2. Autoimmunity/Toxicity
  3. Innate Immune Checkpoints
  4. Combination Treatments (Other Immunotherapies)
  5. Combination Treatments (Chemotherapy, Radiotherapy, Targeted Therapy)
  6. Other

2) Immuno-Conjugates and Chimeric Molecules

  1. Antibody-Drug Conjugates
  2. Antibody-Radionuclides Conjugates
  3. Bispecific Molecules
  4. Response/Resistance Mechanisms
  5. Combination Treatments
  6. Toxicity
  7. Other

3) Cellular Therapies 

  1. Chimeric Antigen Receptors
  2. Non-CAR Adoptive Cell Therapies
  3. Other Cellular Therapies
  4. Response/Resistance Mechanisms
  5. Combinations
  6. Toxicity
  7. Other

4) Immune-Stimulants and Immune Modulators 

  1. Vaccines
  2. Cytokines
  3. Oncolytic Viruses
  4. TLR Agonists
  5. STING Agonists
  6. Intra-Tumoral Agents
  7. Immune Effects of Non-Immunotherapeutic Treatments
  8. Reponses/Resistance Mechanisms
  9. Toxicity
  10. Other

5) Novel Single-Agent Immunotherapies

6) Combination Immunotherapies

  1. Immunotherapy/Immunotherapy
  2. Immunotherapy/Chemotherapy
  3. Immunotherapy/Radiotherapy
  4. Immunotherapy/Targeted Therapy
  5. Immunotherapy/Surgery
  6. Immunotherapy/Other
  7. Response/Resistance Mechanisms
  8. Toxicity
  9. Other

7) Immune Cell Biology

  1. Cellular Metabolism
  2. Innate Immunity
  3. Adaptive Immunity
  4. Antitumor Immunity
  5. Immunogenomics
  6. Epigenetic Regulation
  7. Immunotherapeutic Response/Resistance Mechanisms
  8. Immune Effects of Non-Immunotherapeutic Treatments
  9. Toxicity
  10. Other

8) Tumor and Stromal Cell Biology

  1. Cellular Metabolism
  2. Oncogenetics
  3. Epigenetic Regulation
  4. Tumor Antigens and Others
  5. Virus-Driven Cancers
  6. Cancer-Associated Fibroblasts
  7. Endothelial Cells
  8. Tumor microenvironment
  9. Mouse Models
  10. Toxicity
  11. Other

9) Microbiome and Other Environmental Factors

  1. Immunotherapeutic Response/Resistance Mechanisms
  2. Diet, Exercise and Metabolism
  3. Microbiome
  4. Other

10) Biomarkers, Immune Monitoring, and Novel Technologies

  1. Imaging 
  2. Next-Generation Sequencing
  3. Neoantigen Identification and Characterization
  4. Animal Models
  5. Circulating DNA and Other Blood-Based Soluble Markers
  6. Gene Editing
  7. Bioengineering
  8. Other

11) Machine Learning, Artificial Intelligence, and Computational Modeling

12) Data Sharing, Handling, and Access

  1. New Data Sharing Initiatives
  2. Data Analysis Platforms
  3. Tumor Sample Libraries
  4. Genetic Data Libraries
  5. Combined Tumor Sample/Genetic Data Libraries
  6. Other

13) Immunotherapy Toxicities

  1. Toxicity Management: Clinical Care and Best Practices
  2. Mechanisms of Toxicities
  3. Long-Term Immunotherapy Toxicities
  4. Other

14) Education and Treatment Management

  1. Post-Immunotherapy Treatment Strategies
  2. Patient Experience and Education
  3. Clinician Education
  4. Best Practices for Cancer Immunotherapy Treatment
  5. Case Studies
  6. Other

15) Regulatory, Financial, and Access Considerations

  1. Immunotherapy Cost and Value Analyses
  2. Patient Access Initiatives
  3. Regulatory Considerations
  4. Reimbursement Initiatives
  5. Immunotherapy Clinical Trial Design
  6. Patient Exclusion/Inclusion Criteria
  7. Other

16) Nursing/Pharmacy

  1. irAE Management: Clinical Care and Best Practices
  2. Patient Experience: Patient Education Regarding Immunotherapy and Side Effect Management
  3. Best Practices for Improving Cancer Immunotherapy Treatment Administration and Polypharmacy Management
  4. Case Studies Demonstrating Exceptional Responses or Best Practices for Management of irAEs
  5. Other
17) Immune Cell Types
  1. B cells
  2. T cells
  3. NK cells
  4. Dendritic cells
  5. Non-Conventional cells
  6. Macrophages
  7. Other
18) COVID and Immunotherapy 
19) Other
49093474972_c30afa2b0b_b.jpg
49093474972_c30afa2b0b_b.jpg